First National Bank of Mount Dora Trust Investment Services Has $1.85 Million Stock Holdings in Johnson & Johnson $JNJ

First National Bank of Mount Dora Trust Investment Services cut its position in Johnson & Johnson (NYSE:JNJ) by 4.4% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 12,127 shares of the company’s stock after selling 557 shares during the period. First National Bank of Mount Dora Trust Investment Services’ holdings in Johnson & Johnson were worth $1,852,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of JNJ. Nuveen LLC acquired a new stake in Johnson & Johnson in the first quarter worth $1,369,188,000. Bank of New York Mellon Corp raised its holdings in shares of Johnson & Johnson by 26.4% during the first quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company’s stock worth $3,844,580,000 after acquiring an additional 4,842,582 shares during the period. Pacer Advisors Inc. raised its holdings in shares of Johnson & Johnson by 1,382.0% during the first quarter. Pacer Advisors Inc. now owns 3,030,084 shares of the company’s stock worth $502,509,000 after acquiring an additional 2,825,626 shares during the period. Assenagon Asset Management S.A. raised its holdings in shares of Johnson & Johnson by 159.6% during the second quarter. Assenagon Asset Management S.A. now owns 4,159,260 shares of the company’s stock worth $635,327,000 after acquiring an additional 2,557,388 shares during the period. Finally, Kingstone Capital Partners Texas LLC acquired a new stake in shares of Johnson & Johnson during the second quarter worth $401,420,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This trade represents a 24.08% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.16% of the stock is currently owned by company insiders.

Analyst Ratings Changes

JNJ has been the topic of a number of research analyst reports. Stifel Nicolaus raised their price objective on shares of Johnson & Johnson from $165.00 to $190.00 and gave the stock a “hold” rating in a report on Wednesday. Cowen restated a “buy” rating on shares of Johnson & Johnson in a report on Tuesday. Sanford C. Bernstein raised their price objective on shares of Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a report on Monday, October 6th. Morgan Stanley set a $190.00 price objective on shares of Johnson & Johnson in a report on Wednesday. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $209.00 target price on shares of Johnson & Johnson in a research report on Friday, October 10th. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $199.59.

Johnson & Johnson Stock Up 0.6%

Johnson & Johnson stock opened at $193.27 on Friday. The company has a market cap of $465.45 billion, a P/E ratio of 18.65, a price-to-earnings-growth ratio of 2.27 and a beta of 0.40. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $194.40. The company has a fifty day simple moving average of $180.49 and a 200 day simple moving average of $164.86. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 33.08%. The business had revenue of $24.02 billion during the quarter. Research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is 50.19%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.